Evidence map›Paper›PMID 28068327›Full record

ArticleOncogene2017

CIP2A confirms its prognostic value in triple-negative breast cancer.

I Cristóbal, S Zazo, B Torrejón, M Pedregal, J Madoz-Gúrpide, A Lluch, P Eroles, A Rovira, J Albanell, J García-Foncillas and 1 more

Open access · bronzeAbstract readLetterComment
PubMed Publisher
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

I CristóbalDepartment of Medical Oncology, Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital 'Fundacion Jimenez Diaz', Madrid, Spain.
S ZazoDepartment of Pathology, IIS 'Fundación Jiménez Diaz', Madrid, Spain.
B TorrejónDepartment of Medical Oncology, Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital 'Fundacion Jimenez Diaz', Madrid, Spain.
M PedregalDepartment of Medical Oncology, Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital 'Fundacion Jimenez Diaz', Madrid, Spain.
J Madoz-GúrpideDepartment of Pathology, IIS 'Fundación Jiménez Diaz', Madrid, Spain.
A LluchDepartment of Breast Cancer Research, Institute of Health Research INCLIVA, Valencia, Spain.
P ErolesDepartment of Breast Cancer Research, Institute of Health Research INCLIVA, Valencia, Spain.
A RoviraDepartment of Medical Oncology, Hospital del Mar, Barcelona, Spain.
J AlbanellDepartment of Medical Oncology, Hospital del Mar, Barcelona, Spain.
J García-FoncillasDepartment of Medical Oncology, Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital 'Fundacion Jimenez Diaz', Madrid, Spain.
F RojoDepartment of Pathology, IIS 'Fundación Jiménez Diaz', Madrid, Spain.
Hospital Universitario Fundación Jiménez Díaz · ESHospital Del Mar · ESINCLIVA Health Research Institute · ESUniversidad Autónoma de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cell Line, TumorTriple Negative Breast NeoplasmsAutoantigensBiomarkers, TumorBreast NeoplasmsHumansPrognosisAutoantigensBiomarkers, Tumor

Identifiers

PMID28068327
OpenAlexW2568990594

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.